PTPI — Petros Pharmaceuticals Cashflow Statement
0.000.00%
- $13.33m
- $16.86m
- $5.11m
Annual cashflow statement for Petros Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -20.6 | -8.99 | -20 | -8.16 | -14.3 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 5.65 | -8.06 | 4.73 | -3.37 | 4.36 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -5.6 | -1.69 | -3.09 | 0.625 | 4.53 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -15.3 | -11.9 | -12.8 | -7.63 | -2.6 |
Capital Expenditures | -0.005 | 0 | — | — | -0.025 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.005 | 0 | — | — | -0.025 |
Financing Cash Flow Items | 21.5 | 0 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 30.3 | 18.6 | -1.62 | 11.5 | -7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 15 | 6.71 | -14.4 | 3.91 | -9.63 |